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ABSTRACT

Asparaginase derived from Eschericia coli or Erwinia crysanthum is used in the
treatment of juvenile Acute Lymphoblastic Leukemia (ALL). ALL cells cannot make asparagine
due to the lack of L-asparagine synthetase gene. Asparaginase is therefore used as a
chemotherapeutic treatment for ALL through hydrolysis of the L-asparagine to aspartic acid,
which leads to starvation of the ALL tumor cells, then apoptosis. In addition, the asparaginase
enzyme is used in the food industry. Asparaginase can be used to reduce acrylamide in baked
food formed during the Milliard reaction. In this study, in this study, Rhodococcus rhodochrous

DAP 96253 asparaginase enzyme activity is measured at varying temperatures (27 °C and 37 °C)
and substrate concentrations, using colorimetric reagents, to determine the enzyme reaction
stability with respect to these variables. Asparaginase enzyme activity increases by increasing
the temperature to a specific optimal point, after that it declines. This accelerates the hydrolysis
of L-asparagine to L-aspartic acid. The goal is to determine the optimum temperature for the
enzyme function.

INDEX WORDS Asparaginase activity, ALL, Glutaminase, Rhodococcus rhodochrous DAP
96253.
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1

INTRODUCTION

1.1 Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a blood and bone marrow cancer which affects
white blood cells (Patra et al. 2014). Juvenile ALL is considered one of the most common forms
of cancer among children and adolescents in the United States (Siegel et al. 2018). Around 6000
cases in the United States are diagnosed annually with acute lymphoblastic leukemia; half of
these cases occur in children and teenagers (Stephen et al. 2015). The childhood ALL patients’
treatment has advanced to the extent that 5 years event free survival rates reached around 80%
(Evans, 1998). There are many factors that contribute to the poor outcome in adults’ ALL
treatment, and the increased frequency of high-risk leukemia, such as poor tolerance of and
compliance with treatment, great drug resistance, less effective treatment regimens, and the
changes in the physiology and organ function affecting the pharmacology of ALL therapy, in
comparable with childhood ALL (Musa et al. 2017).

1.1.1

Asparaginase mechanism of action
Asparaginase can be isolated from different bacteria such as Escherichia coli (E.coli),

Erwinia crysanthum, Rhodococcus rhodochrous and Pseudomonas pseudocaligines (Dalfard,
2016). Asparaginase formulations derived from E. coli and Erwinia crysanthum are currently
used in the treatment of juvenile acute lymphoblastic leukemia. Asparaginase hydrolyzes Lasparagine to L-aspartic acid and ammonia in tumor cells that do not have L- asparaine
synthetase. This results in starvation of the tumor cells due to depletion of L-asparagine and then
the protein synthesis inhibition (Karl et al. 2017). Asparagine is considered critical for protein
synthesis in leukemic cells that cannot synthesize this amino acid due to the deficient or the
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absence of enzyme asparagine synthetase (Neil, 2009). Despite, the prominent role of Lasparaginase in treating acute lymphoblastic leukemia, the use is still limited due to the high
adverse side effects associated with it such as pancreatitis, nephrotoxicity and neurological
problems. These side effects of L-asparaginase usually occur as a result of the dual substrate
specificity towards glutamine and asparagine (Ramia et al, 2012). The L- asparaginase leads to
decrease the glutamine levels in circulation through the deamination of glutamine to glutamic
acid (Grigoryan et al. 2004). The glutamine decreasing leads to depletion of tumor growth and
enhancing cell apoptosis, as glutamine is believed to be a source of nitrogen, which plays a role
in synthesis of DNA and RNA by the tumor cells (Cory et al.2006).

Figure 1 L-asparaginase mode of action in healthy and tumor cells.
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1.1.1.1 Asparaginase role in treatment of Acute Lymphoblastic Leukemia (ALL)

Acute lymphoblastic leukemia (ALL) is one of the most progressive and common cancers
in children. Asparaginase is recognized for treating acute lymphoblastic leukemia with 90 %
complete remission in children and adults (Piatkowska et al. 2008). Asparaginase leads to
starvation of the tumor cells then subsequent apoptosis. Three asparaginase forms derived from
different bacteria have the same mechanism of action, yet each asparaginase displays a uniquely
different pharmacokinetics profile. These three forms include Erwinia asparaginase, Escherichia
coli and pegylated form of the native E.coli asparaginase (pegaspargase) (Asselin, 1999).
Escherichia coli PEGylated asparaginase is used as first line therapy for acute lymphoblastic
leukemia. However, it displayed hypersensitivity in 30% of patients (Egler et al. 2016). The
antibodies against E.coli-asparaginase lead to these hypersensitivity reactions and silent
inactivation of E.coli asparaginase in up to 60% of cases (Rob et al.2011). The PEGylated
asparaginase derived from Escherichia coli has a less immunogenic potential and a longer halflife than the native E.coli. In addition, it is more feasible with intravenous injection (Vrooman et
al.2015). In European and US protocols, the asparaginase derived from Erwinia chrysanthemi
acts as second or third line of therapy after E.coli hypersensitivity (Pieters et al. 2011). Patients
switch to another asparaginase form to decrease the hypersensitivity derived from Gramnegative bacteria. One of the most frequent and serious complications of acute lymphoblastic
leukemia the treatment are the thromboembolic events (TEs) (Sutor, 1992). In juvenile acute
lymphoblastic leukemia, the timing of TEs occur after the chemotherapy with L- asparaginase
immediately or during the treatment (kuknar et al. 1985). These thromboembolic events may
lead to neurological sequela and significant morbidity in acute lymphoblastic leukemia patients
(Vijaya et al. 2015).

4

2
2.1

BACKGROUND

Rhodococcus rhodochrous DAP 96253 bacteria
Rhodococcus rhodochrous is a Gram positive, aerobic, and non-motile bacterium

(Warhurst, 1994). Rhodococcus classification is mainly based on its distinctive composition of
mycolic acids (Larkin et al. 2010). All the Rhodococcus strains start their life as coccus or short
rod shape, their morphology change upon growth into various forms: hyphae, short rods and
filaments. Formation of new generation occurs at the end of the exponential growth stage via
fragmentation of the matured individuals (Goodfellow et al, 1998). Rhodococcus rhodochrous
has the capability of using a wide range of organic compounds as sources of carbon and energy
for their growth (Goodfellow et al. 1998). Rodococcus rhodochrous is known to be closely
related to Cornebacterium, Mycobacterium and Nocardia by analysis of 16SrDNA (Bell et al.
1998).
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Figure 2 Rhodococcus rhodochrous Dap 96253 (AEM Pierce).

2.1.1 Rhodococcus rhodochrous strains and pathogenesis
Rhodococcus genus members inhabit diverse niches, cause pathogenesis in mammals
and plants. However, Rhodococcus rhodochrous, which is isolated from contaminated soil, does
not possess any pathogenesis (Larkin et al. 2010). Some of the Rodococcus rhodochrous strains,
like ATCC 17895, showed the optimal growth on cultural media at 26 OC within 3 to 4 days.
That leads to dry opaque and pale orange colonies (Christopher et al. 2011). Many Rhodococcus
strains are considered as a significant part of the soil microbial community due to the diversity of
their biodegradation mechanisms (Larkin et al. 2010). In addition, some of the Rhodococcus
rhodocrous strains are exploited in industrial production and pollutants degradation (Warhurst,
1994). Rhodococcus strain 11Y, which is isolated from explosives-contaminated land, uses RDX
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(hexahydro-1,3,5-trinitro-1,3,5-triazine) as a sole nitrogen source for growth (Zhao et al. 2004).
Rodococcus rhodochrous has a diverse array of organic compounds degradation capabilities
which contributed by its large genome size (Bell et al. 1998). There are a massive number of
biodegradative, and catabolic genes stored in their large linear plasmids. Rhodococcus has
generally increased in scientific research due to its highly diverse ability to biodegrade (Bell et
al. 1998). Thus, revealing their commercial potentials Rodococcus rhodochrous strains possess a
variety of biotransformative capabilities. For example, the short chain hydrocarbons
Rhodococcus rhodochrous E5, is able to degrade acetylene via acetaldehyde to acetyl
CoA.While Rodococcus rhodochrous ATCC21198 shows the ability to grow on propane with
CO2 presence as it contributes to the fixation of CO2 (Warhurst,1994). Some strains of
Rodochococus rhodochrous, KUCC 8801 and KUCC 8802, demonstrate the ability to degrade nalkanes; other strains of R. rhodochrous are specialist in long-chain hydrocarbons degradation
(Warhurst, 1994). The biotransformation of nitriles would be a successful applied aspect of R.
rhodochrous, as R. rhodochrous J1 produces nitrile hydratase that is used to produce more than
30,000 tons of acrylamide from acrylonitrile annually for commercial purposes (Bell et al. 1998).
When catalyst derived from cells of R. rhodochrous strain DAP 96253 on YEMEA, which is
supplemented with urea, cobalt, and Asparagine showed a great impact in delaying fruits
ripening, in addition it was noted that it had the highest level of Nitrile hydratase (Pierce et al.
2011).
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3

RATIONALE

Asparaginase is an enzyme that is purified from Rhodococcus rhodochrous DAP 96253
bacteria; it accelerates the hydrolysis of l-asparagine to l-aspartic acid and ammonia ,which could
leads to inhibition of protein synthesis in tumor cells through deprivation them from amino acid
asparagine (Karl et al, 2017). Asparaginase is also considered as a recognized part in treatment
of acute lymphocytic leukemia (Neil, 2009). Since asparaginase is derived from a Gram positive
bacteria Rhodococcus rhodochrous DAP 96253, this could be safer, and better than the
asparaginase derived from Gram negative bacteria like Escherichia coli (E.coli) and Erwinia
crysanthum, which possess hypersensitivity.
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HYPOTHESIS

It is hypothesized that Rhodococcus rhodochrous DAP 96253 asparaginase enzyme
activity increases by increasing the temperature to a specific optimal point after that it declines.
This accelerates the hydrolysis of L-asparagine to L- aspartic acidand ammonia, and thus led to
deprivation of the L- asparagine in the acute lymphoblastic leukemia tumor cells then cell death
(apoptosis).

9

5
5.1

AIMS

Determine the effects of different temperatures on asparaginase activity.
Exposing Rhodococcus rhodochrous DAP 96253 asparaginase and the substrate

concentrations to different temperatures 27 °C and 37 °C, and noticing the corresponding results
and the effects on the asparaginase and glutaminase activity by using thermomixer R with
different Substrate concentrations.
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6

MATERIALS AND METHODS

1. 96 well plates u bottoms.
2. L-Asparagine, minimum 98% TLC.
3. Glutamine.
4. 4 N NaOH (dissolve 3.2g NaOH in 2oml of distilled H2O)
5. 4N H2SO4 (Mix 4.4ml of 18N stock H2SO4 with 15.6 distilled H2O)
6. 25% Sodium phenate (dissolve 25g of phenol in 800 ml distilled H2oO and add 78 ml of 4N
NaOH, bring volume to 1000ml)
7. 0.01% sodium nitroprusside (mix 10 ml of 1% sodium nitroprusside stock solution with 990ml
distilled H2O)
8. 0.15% Sodium hypochlorite (mix 25 ml of 6% sodium hypochlorite with 975ml of distilled
H2O)
9. Stock Ammonium (1000 ppm Ammonium) made using NH4Cl.
10. DDH20.
11. Thermomixer R.
12. Viktor plate Spectrophotometer.
13. Laser Grip 1080 (infrared thermometer).
14. Thermometer.
*All chemicals unless otherwise stated were from Sigma.
Measuring the purified Rhodococcus rhodochrous DAP 96253 asparaginase and glutaminase
enzyme activity with varying temperatures. The temperatures selected include 27 °C and 37 °C
(body temperature 37°C), these varying temperatures were maintained using thermomixer hot
plate. Asparagine and glutamine substrate concentrations tested include 500ppm which is the
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average concentration, and time points tested include 2 minutes to determine the enzyme stability
with respect to these variables. The asparagine solution and the glutamine solution were made by
adding L-asparagine to sodium phosphate buffer pH 7.2 to the desired concentration, and the
glutamine solution was made by phosphate buffer 7.2 enzyme and substrates controls as well as
ammonia standards were made. The ammonia standard were made from Stock Ammonium
(1000 ppm Ammonium) using NH4Cl. 100 µl of enzyme was added to triplicate Eppendorf tubes
of 900 µl of asparagine substrate and 900 µl of glutamine substrate agitated to initiate the
reaction for the desired time period, after which 10 µl of 2M sulfuric acid (Mix 4.4ml of 18N
stock H2SO4 with 15.6 distilled H2O) was added and then vortexed to stop the reaction. 10ul of
4N NaOH (dissolve 3.2g NaOH in 2oml of distilled H2O) was added to the reaction to neutralize
the acid, after which the samples were transferred to the test tubes. Colorimetric reagents of 2 ml
of 25% Sodium phenate (dissolve 25g of phenol in 800 ml distilled H2oO and add 78 ml of 4N
NaOH, bring volume to 1000ml), 3ml of 0.01% sodium nitroprusside (mix 10 ml of 1% sodium
nitroprusside stock solution with 990ml distilled H2O), and 3 ml of 0.15% Sodium hypochlorite
(mix 25 ml of 6% sodium hypochlorite with 975ml of distilled H2O) were added respectively
and the solutions were vortexed. Test tubes were incubated at room temperature in the dark for
30 minutes at least. 200 µl reaction sample from each test tube was pipetted onto 96 well plates
(u bottom) and optical density was measured at 630nm using a Viktor plate Spectrophotometer.
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7

RESULTS AND DISCUSSION

Asparaginase enzyme activity
(U/min/ml) and the reaction time
period at 37⁰C .
2000
1500
1000
500
0
2

10

20

30

enzyme activity(U/min/ml)

Chart 1 1000 ppm asparaginase enzyme activity (U/min/ml) at different reaction time
points 2, 10, 20 and 30 minutes at 37°C.

Asparaginase enzyme activity
(U/min/ml) and the reaction time
period at 25⁰ C .
400
300
200
100
0
2

10

20

30

enzyme activity(U/min/ml)

Chart 2 1000 ppm asparaginase enzyme activity (U/min/ml) at different reaction time
points 2, 10, 20 and 30 minutes at 25°C.
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600
500
400
300

Glutaminase enzyme
Activity

200

Asparaginase enzyme
activity

100
0
27 °C

37 °C

Chart 3 The aspargainase and the glutaminase enzyme activity (U/min/ml) at
(2minutes) reaction at 27 °C and 37°C temperatures, 500 ppm asparagine and glutamine
substrate concentration.

*Chart (1) and Chart (2) indicate that the enzyme activity of asparaginase substrate
solution of 1000 ppm concentration at different time reaction periods (2, 10, 20 and 30 min), was
decreasing with respect to the time periods at 10, 20 min and 30 min reaction. The Optimal
enzyme activity was determined to occur at the 2 minutes time point at different temperatures 25
°C and 37°C.

* Chart (3) indicates that the enzyme activity of asparaginase substrate solution 500 ppm
and the enzyme activity of glutaminase substrate solution 500 ppm concentration were increasing
by increasing temperature from 27 °C to 37 °C at 2 min time reaction, which indicates that the
enzyme activity for both the Asparaginase and Glutaminase increases by increasing temperature
at 37 °C.
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Table 1 The samples (2 minutes) reaction 27 °C and 37°C temperatures, 500ppm
Asp substrate concentration
Asparagine
substrate conc.(ppm)

Enzyme
Temperatures

activity(u/min/ml)

27°C

< 0.1

37°C

3

500 PPM

15

Table 2 The samples (2minutes) reaction at 27 °C and 37°C temperatures, 500 ppm
glutamine substrate concentration
Glutamine
Enzyme
substrate

Temperatures

activity(u/min/ml)

conc.(ppm)

27°C

135

37°C

90

500 PPM

* Table (1.1) and table (1.2) indicate that with (500ppm) asparagine substrate
concentration the enzyme activity was increasing by increasing temperature at 37 °C. That shows
that the asparagine enzyme activity increased by temperature. While, the enzyme activity of 500
ppm glutamine substrate, show a decrease in the enzyme activity at 37 °C temperature. As a
result of unequal protein distribution in the sample that contain low protein concentration
0.002mg/ml. These results based on using 100ul of enzyme and 900ul of substrates concentration
were related to the more color intensity showed during the reaction by using 100ul volume
instead of other lower volumes that have faint color that make it hard to detect the enzyme
activity with colorimetric reagents. In addition, if the sample of 100ul enzyme contains a high
protein concentration equally distributed (homogenous) among the volume, this will result in a
more consistent increase or decrease in the asparaginase and glutaminase enzyme activity
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respectively with increasing temperatures to 27 °C at 37 °C at 2 min time reaction. While if the
sample of 100ul contains a low protein concentration with uneven distribution that will result in
fluctuation and inconsistent of the glutaminase enzyme activity results with increasing
temperature.
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CONCLUSION

This study is directly relevant to the enzyme stability reaction for Rhodococcus
rhodochrous DAP 96253 asparaginase as a potential treatment for acute lymphoblastic leukemia.
This study uses a new form of derived asparaginase, through switching from Gram negative
bacteria (Eschericia coli and Erwinia crysanthum) asparaginase to a Gram-positive bacteria
Rhodococcus rhodochrous DAP 96253 asparaginase. Asparaginase derived from Rhodococcus
rhodochrous DAP 96253 could be safer, more stable, and less immunogenic to the patients. In
this study, the asparaginase and glutaminase activity were increasing by increasing temperature
from 27 °C to 37 °C at 2 min time reaction. That indicates it will be stable during storage at 4°C
in refrigerator and active inside our body temperature 37 °C when used as a medication. Thus,
asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in tumor cells that do not
have L- asparagine synthetase, these results in starvation of the tumor cells due to depletion of Lasparagine and then the protein synthesis inhibition. Also, the L- asparaginase leads to decrease
the glutamine levels in circulation through the deamination of glutamine to glutamic acid and the
glutamine decreasing leads to depletion of tumor growth and enhancing cell apoptosis.
Furthermore, this study will improve the quality of the therapeutic use, and maintain the optimal
stability during storage. In general, translating this research into medical practice and meaningful
health outcomes will enhance the human health and well-being of ALL patients. Due to the fact
that, acute lymphoblastic leukemia is considered one of the most common forms of cancers in
children in the US.so this study is considered patient-and population oriented. That means the
public gets a significant return on investment with the clear objective of having a more positive
impact on our health. Also, the stability of enzyme during storage and the therapeutic use means
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it can be designed to reach the rural and urban communities without affecting the outcomes; this
will improve the access to quality health care and service throughout the health care system.
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9

FUTURE STUDIES

Asparaginase enzyme activity that are purified from Rhodococcus rhodochrous DAP
96253 are increasing by increasing temperatures from 27 °C to 37 °C at 2 min time reaction.
However, Rhodococcus rhodochrous DAP 96253 asparaginase and glutaminase enzyme activity
can be measured among further temperatures above 37 °C until reaching the optimal activity of
the enzyme, which after that it declines. Moreover, further stability reactions can be done.
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